We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.07+0.5%Jul 12 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen8/22/2005 4:06:22 PM
   of 347
GenoMed Adds Dr. Richard Reece to Business Development Advisory Board

David Moskowitz MD FACP
GenoMed, Inc.
tel. 314-983-9933

ST. LOUIS--(August 22, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets symbol GMED) announced today the addition of Dr. Richard Reece, a prolific and influential medical writer, to its Business Development Advisory Board.

Dr. Richard Reece is a pathologist, writer, editor, and author. He has served as editor-in-chief of Physician Practice Options, a monthly newsletter for practicing physicians for nine years. The newsletter has variations that reach cardiologists, nephrologists, and oncologists. He is the author of four books. The latest is Voices of Health Reform (Practice Support Resources, Inc, 2005) consisting of 41 interviews with leading health care authorities. He also writes frequently for, which is read by 50,000 health care leaders each day. He serves on the advisory boards of the Center for Practical Health Reform and America's Top Doctors, a 1300 page book listings America's top doctors, based on nominations of other doctors.

Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "Dr. Reece is a leader in developing practical approaches to health care reform, including consumer-directed healthcare. We are honored to have his help in crafting and delivering GenoMed's message of cost control and quality improvement to medical societies, health plans, and business coalitions."

About GenoMedTM

GenoMed, Inc. is a Next Generation DMTM company whose mission is to improve patient outcomes by identifying the molecular pathways or genes that cause disease. A St. Louis Business Journal article ( first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema. The company is also conducting a free clinical trial for West Nile virus; to enroll, simply click on the West Nile virus link at

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext